LordsMark Industries Ltd announces a significant milestone with the filing of a patent for its latest line of bio-chemistry reagents. Developed under the flagship brand LordsMed, these reagents mark a pivotal advancement in diagnostic accuracy and accessibility.
Boasting an unparalleled accuracy of 99.7 percent and an extended shelf-life of 24 months, these reagents offer a robust solution for medical professionals and patients alike. The comprehensive range covers vital biomarkers including Triglycerides, Uric Acid, and Glucose, addressing critical needs in preventive healthcare. Key to this endeavor is LordsMark’s expansive Pan-India distribution network, comprising over 300 dealers, ensuring widespread availability and seamless access to these groundbreaking products. Additionally, the company is poised to penetrate global markets, with plans to export to SAARC, African, and Eastern European countries.
Sachidanand Upadhyay, MD of LordsMark Industries Ltd, underscores the strategic importance of this patent, stating, “Our commitment to innovation and excellence drives us to redefine diagnostic standards, empowering healthcare providers with advanced tools for early detection and intervention.”
